TG Therapeutics (TGTX) Tops Q4 EPS by 7c, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)
March 3, 2025 1:07 PM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
The analyst comments "TGTX stock is up >18% (XBI: -1%) on the back of positive comments on the 4Q call around 1Q trends for Briumvi (anti-CD20 drug in... More
